

## Total Voting Rights

01 November 2017 15:00 GMT

### Transparency Directive

#### Voting Rights and Capital

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 October 2017 the issued share capital of AstraZeneca PLC with voting rights is 1,265,948,818 ordinary shares of US\$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,265,948,818.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

#### About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit [www.astrazeneca.com](http://www.astrazeneca.com) and follow us on Twitter @AstraZeneca.

#### Media Relations

|                     |  |                  |
|---------------------|--|------------------|
| Esra Erkal-Paler    | UK/Global  | +44 203 749 5638 |
| Karen Birmingham    | UK/Global  | +44 203 749 5634 |
| Rob Skelding        | UK/Global  | +44 203 749 5821 |
| Matt Kent           | UK/Global  | +44 203 749 5906 |
| Gonzalo Vñia        | UK/Global  | +44 203 749 5916 |
| Jacob Lund          | Sweden   | +46 8 553 260 20 |
| Mchele Meixell      | US   | +1 302 885 2677  |
| Investor Relations  |  |                  |
| Thomas Kudsk Larsen |  | +44 203 749 5712 |
| Craig Marks         | Finance, Fixed Income, M&A                       | +44 7881 615 764 |
| Henry Wheeler       | Oncology   | +44 203 749 5797 |
| Mitchell Chan       | Oncology   | +1 240 477 3771  |
| Christer Gruvris    | Diabetes; Autoimmunity, Neuroscience & Infection | +44 203 749 5711 |
| Nick Stone          | Respiratory; Brilinta                            | +44 203 749 5716 |
| US toll free        |  | +1 866 381 7277  |

#### Adrian Kemp

Company Secretary, AstraZeneca PLC